Clinical Development of Viekira Pak to Mavyret
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/7355_2018_60
Reference35 articles.
1. McDaniel K (2018) The discovery and development of HCV NS3 protease inhibitor paritaprevir. Top Med Chem. https://doi.org/10.1007/7355_2018_42
2. Wagner R (2018) HCV NS5A as an antiviral therapeutic target. From validation to the discovery and development of ombitasvir and paritaprevir as components of IFN-sparing HCV curative treatments. Top Med Chem. https://doi.org/10.1007/7355_2018_50
3. Rong L, Dahari H, Ribeiro RM, Perelson AS (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2:30ra32
4. Gane EJ, Roberts SK, Stedman CAM et al (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467–1475
5. Lawitz E, Poordad F, Kowdley KV et al (2013) A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 59:18–23
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Curing Hepatitis C with Direct‐Acting Antiviral Therapy;New Drug Development for Known and Emerging Viruses;2021-12-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3